je.st
news
Tag: results announces
KCS announces results of Holiday Express fundraising campaign
2014-11-20 10:11:53| Railroads - Topix.net
KANSAS CITY, Mo. - Kansas City Southern announced today that its 14th Annual Holiday Express will distribute $150,175 in gift cards to The Salvation Army at stops along the Holiday Express route.
Tags: results
express
holiday
campaign
Tyson Foods (TSN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS
2014-11-17 17:12:51| Food - Topix.net
Tyson Foods released its earnings data on Monday. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.11, Analyst Ratings.Net reports.
Tags: results
estimates
quarterly
foods
Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase...
2014-11-15 20:32:22| Biotech - Topix.net
Keryx Biopharmaceuticals, Inc. today announced results from a 48-week Open Label Extension safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster at the 2014 American Society of Nephrology's Kidney Week meeting in Philadelphia, PA.
Tags: results
phase
announces
citrate
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
LSI Industries (LYTS) Announces Quarterly Results
2014-11-10 15:56:33| Furniture - Topix.net
LSI Industries released its earnings data on Monday. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.04 by $0.02, American Banking & Market News reports.
Tags: results
industries
quarterly
announces
Sites : [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] next »